Combination chemotherapy for metastatic breast cancer. - Wikidata - wikimedia - TriplyDB

Combination chemotherapy for metastatic breast cancer.

Combination chemotherapy for metastatic breast cancer.

http://www.wikidata.org/entity/Q34734518

about

Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model Emerging candidates in breast cancer stem cell maintenance, therapy resistance and relapse.Serum tumor markers in patients with breast cancer.The role of taxanes in the treatment of breast cancer.Gemcitabine in metastatic breast cancer.Docetaxel in the treatment of breast cancer: current experience and future prospects.Anti-Lung-Cancer Activity and Liposome-Based Delivery Systems of β-Elemene Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer

P2860

Q34755674-4426606C-3DF5-4EFD-9D0F-D38D8EC4131E Q35686250-29F7A7E3-EAA7-49B5-94A6-E216D39DCB58 Q35918479-4AE04EE2-C30B-4CD3-B329-F72C0DCE4355 Q36163956-021B4097-F893-4CD7-869E-F52B64D24B87 Q36185611-C64D5EEF-1C02-4EBA-81B4-1BD68EA84ED4 Q36235546-7B9109C7-F405-4D6A-9E18-E2DA5DA42F66 Q36457949-96004E68-2230-408A-B4DE-CB6B9C8EBE38 Q36695861-80BA5F26-5611-418A-9720-0F5AAD9AE00A

P2860

Combination chemotherapy for metastatic breast cancer.

http://www.wikidata.org/entity/Q34734518

description

2002 nî lūn-bûn

@nan

2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Combination chemotherapy for metastatic breast cancer.

@ast

Combination chemotherapy for metastatic breast cancer.

@en

Combination chemotherapy for metastatic breast cancer.

@nl

type

label

Combination chemotherapy for metastatic breast cancer.

@ast

Combination chemotherapy for metastatic breast cancer.

@en

Combination chemotherapy for metastatic breast cancer.

@nl

prefLabel

Combination chemotherapy for metastatic breast cancer.

@ast

Combination chemotherapy for metastatic breast cancer.

@en

Combination chemotherapy for metastatic breast cancer.

@nl

P1433

Q34734518-F5CE8F3B-3B9B-4C8D-8335-3678D7D4F35D

P1476

Q34734518-21B79FE1-7631-494A-AC27-55B986E75D62

P2093

Q34734518-52BADF11-25D6-4894-BF61-84A80BB36A84

Q34734518-93A55972-A00B-4D57-A872-481289AABF6A

Q34734518-EE7B884D-7143-47D1-9EF2-F87464AC8890

Q34734518-F6440DA1-2D14-4D1B-8C44-8E03DF85751F

P2860

Q34734518-07948F63-84A2-4133-B72B-8A168AE2DDA8

Q34734518-65F5092C-1EAE-457F-887E-BA431709F70D

Q34734518-77E6B522-97E5-43DA-9E2E-99D19020170C

Q34734518-82ACBEA6-DFE4-40EE-AE58-925165C3E7E6

Q34734518-A0270A9A-E6C0-4B6E-A014-23D45BEAF95F

Q34734518-A893BF68-9665-4FC6-AD34-9E30B4C5ABD1

Q34734518-AA5DD1DB-ABD6-44B6-B315-50B74C13A349

Q34734518-D21FD62B-0325-4D15-B844-7C6351286AF4

Q34734518-DA6E02A1-4565-4790-84B4-6F397C73D4AC

Q34734518-E1B026A6-53E6-416A-9D84-FC1F41E1FD38

P304

Q34734518-A06F78EC-9285-40EA-97A9-BD016A6A9B52

P31

Q34734518-43208BE0-1517-4E2A-A395-B6BCB712F1E7

P356

Q34734518-683D67F7-5C12-471F-8B24-0B974D42648C

P433

Q34734518-2E444BD6-BBF5-4E63-A691-9CF65AB19321

P478

Q34734518-3D876E6A-B80C-41AA-A5B4-183A02A1F924

P577

Q34734518-B7EA9E84-FE6E-4A17-8816-0F36C95AC900

P5875

Q34734518-1AFC3175-FE4D-4036-BD83-E8C3BAFB5DEF

P698

Q34734518-8B46ACEA-2CB4-4B7A-AA9F-071D51153E7F

P921

Q34734518-BEA261B2-CF6C-459F-8C2B-30F4A94B8BE2

P356

14737140.2.2.169

P1433

Expert Review of Anticancer Therapy

P1476

Combination chemotherapy for metastatic breast cancer.

@en

P2093

Alessandro Riva

http://www.w3.org/2001/XMLSchema#string

David M Reese

http://www.w3.org/2001/XMLSchema#string

Jean-Marc A Nabholtz

http://www.w3.org/2001/XMLSchema#string

Mary-Ann Lindsay

http://www.w3.org/2001/XMLSchema#string

P2860

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer.

Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer.

Capecitabine: preclinical pharmacology studies.

Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond.

A systematic overview of chemotherapy effects in breast cancer.

Paclitaxel (taxol)

The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium

Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer.

P304

169-180

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.2.2.169

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P577

2002-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11265848

http://www.w3.org/2001/XMLSchema#string

P698

12113239

http://www.w3.org/2001/XMLSchema#string

P921